MR and ultrasound biopsies combined can detect prostate cancers, says study

Huge Two-Day Clean Sweep Auction July 24-25th. Click Here to Bid!

advertisement
Posição atual:
>
> This Story


Início de uma sessão ou Registo to rate this News Story
Forward Printable StoryPrint Comment

 

advertisement

 

MRI Homepage

Study advises personalized breast cancer screenings for cancer survivors May benefit from MR alone, rather than MR and mammography

Knitting raises thousands for Scottish MR scanner fundraising campaign Improving access to care in remote Shetland Islands

CT and MR waiting times costing Canadians over $3 billion Need $4.4 billion to update imaging stock, says report

Demand on the rise for MR-guided radiotherapy, says new report Compound annual growth rate of 20 percent through 2028

Breast MR for cancer survivors may result in unnecessary biopsies No difference in sensitivity compared to mammography alone

SEC probes Siemens, GE and Philips over business with China Lawsuit alleges OEMs worked together to fix prices on medical equipment

Ezra launches direct-to-consumer full-body MR scanning program Full-body imaging for $1,950 or single-region starting at $675

FDA okays Philips' MR-only radiotherapy simulator, MRCAT pelvis Create treatment plans for bladder, rectal, anal and cervical cancer

Bruker and the Champalimaud Foundation to develop first 18 Tesla UHF MR scanner Enable discovery of new contrast mechanisms

Whole body MR may support faster, less expensive cancer treatment planning A single scan for planning and staging, but challenges remain

Ultrasound- and MR-guided biopsies
together detect up to 33 percent more
tumors in the prostate

MR and ultrasound biopsies combined can detect prostate cancers, says study

por John R. Fischer , Staff Reporter
Combining MR- and ultrasound-guided biopsies for prostate cancer diagnosis may enable detection of over 30 percent more tumors, says a study in California.

Researchers at UCLA have found that while not often used together, combining the traditional method of ultrasound imaging with MR imaging can allow clinicians to detect up to 33 percent more cancers.

Story Continues Below Advertisement

THE (LEADER) IN MEDICAL IMAGING TECHNOLOGY SINCE 1982. SALES-SERVICE-REPAIR

Special-Pricing Available on Medical Displays, Patient Monitors, Recorders, Printers, Media, Ultrasound Machines, and Cameras.This includes Top Brands such as SONY, BARCO, NDS, NEC, LG, EDAN, EIZO, ELO, FSN, PANASONIC, MITSUBISHI, OLYMPUS, & WIDE.



“Our research suggests that the different biopsy methods identify different tumors,” senior author Dr. Leonard Marks, the Jean B. deKernion chair in the department of urology at the David Geffen School of Medicine at UCLA, said in a statement. “To maximize our ability to identify prostate cancer, we need to take advantage of all the information we can. Our cancer detection rate, while using different methods in tandem, surpasses that from using either method alone. In this case, one plus one equals three.”

One million men in the U.S. undergo biopsies annually to determine if they have prostate cancer, many of which use ultrasound-guided imaging to visualize the prostate and allow clinicians to take a representative sampling of tissue. Ultrasound, however, is unable to clearly display the location of tumors in the prostate gland.

MR-guided biopsies, in contrast, are more targeted and enable clinicians to locate specific lesions and take tissue samples only from those spots. As a result, such procedures have become more commonplace in the last decade. But while research has demonstrated the advantages of MR-guided biopsy, how to apply it has been unclear. Some tumors also do not appear as lesions on MR scans, preventing them from being detected.

The team carried out a 300-person study over a three-year period. In that time, MR located a prostate lesion in 248 men. Using available biopsy information and both methods together, researchers detected cancer in 70 percent of them. While MR did not detect lesions in the other 52 men, 15 percent were found to have cancer after undergoing ultrasound-guided biopsies, proving that MR cannot detect all lesions. The authors say the trial is the first to directly compare the different biopsy sampling methods in the same group of men.

“Men being assessed for prostate cancer should first receive an MR before biopsy,” said Marks, who is also the co-founder of Avenda Health, a biomedical device company aiming to treat prostate tumors with a laser device. “When there’s a lesion on MR, physicians should take systematic and targeted biopsies together for the best chance at finding cancer. Even if the MR is negative for lesions, men at risk — including those with elevated levels of prostate-specific antigen, a prostate nodule, or family history — should still receive a traditional, systematic biopsy.”

The ability to identify precise locations of tumors in the prostate is becoming more significant, as treatments become more targeted. Focal therapy, for instance, could eliminate cancerous tissue in the gland without destroying healthy tissue, making it an alternative to prostatectomy, a common and invasive treatment in which the entire gland is surgically removed.

Funding for the study was provided through a grant from the National Cancer Institute, as well as by the Jean Perkins Foundation, the Kent Kresa Family Foundation, and the Steven C. Gordon Family Foundation.

The findings were published in JAMA Surgery.

MRI Homepage


You Must Be Logged In To Post A Comment